Treatment of Relapsed and Refractory AML with Mitoxantrone and Etoposide: A Study of the Eastern Cooperative Oncology Group
The treatment of relapsed and refractory AML remains unsatisfactory. It has generally been assumed that, for such patients, the possibility of long-term disease-free survival when treated with chemotherapy is almost negligible. The main focus of therapy rests with attempts to optimize the likelihood of achieving a complete remission (CR) and then either prolong the CR [l] or attempt to induce a long-term disease-free survival using some form of intensive chemotherapy or bone marrow transplantation.
KeywordsToxicity Leukemia Oncol Diarrhea Neutropenia
Unable to display preview. Download preview PDF.
- 4.Arlin Z, Silver R, Cassileth PA et al. (1984) Phase I/II trial of mitoxantrone in acute leukemia. Cancer Treat Rep 69: 61–64Google Scholar
- 7.Van Echo DA, Wiernik PH, Aisner J (1980) High-dose VP-16-213 for the treatment of patients with previously treated acute leukemia. Can Clin Trials 3(4): 325–328Google Scholar
- 9.Rowe JM, Mazzan JJ, Hines JD et al. (1990) Mitoxantrone and etoposide in patients with relapsed and refractory acute non-lymphocytic leukemia. Acute Leukemias II ed. Buchner et al. In Hematology and Blood Transfusion 33: 326–329, Springer-Verlag, Berlin HeidelbergGoogle Scholar
- 10.Rowe JM, Oken MM, Cassileth PA et al. (1992) Clinical trials in adults with relapsed and refractory acute myelogenous leukemia. The ECOG and University of Rochester experience. Acute Leukemias III ed. Hiddemann et al. In Hematology and Blood Transfusion 34: 392–395, Springer-Verlag, Berlin, HeidelbergGoogle Scholar
- 14.Lazzarino M, Morra E, Alessandrino EP (1988) Mitoxantrone-etoposide combination chemotherapy for relapsed and refractory acute myeloid leukemia (AML) in adults. Blood 72(5): 210a (abstr)Google Scholar
- 15.Hiddemann W, Buchner T (1990) Treatment strategies for relapsed acute myeloid leukemia - a proposal based on the definition of refractoriness against conventional chemotherapy (1990) in Acute Myelogenous Leukemia: Progress and Controversies ed. Gale RP, Wiley-Liss, Inc. 363–373Google Scholar